Table 1 Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm+ NSCLC treated with first-line afatinib (n = 125) in our cohort
From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Characteristic | No. | % |
|---|---|---|
Sex | ||
Male | 64 | 51.2 |
Female | 61 | 48.8 |
Age at diagnosis, years | ||
Median | 62 | |
Range | 26–86 | |
Ethnicity | ||
Chinese | 100 | 80.0 |
Malay | 14 | 11.2 |
Indian | 3 | 2.4 |
Others | 8 | 6.4 |
Smoking status | ||
Never | 95 | 76.0 |
Former | 17 | 13.6 |
Current | 13 | 10.4 |
Histotype – NSCLC | ||
Adenocarcinoma | 121 | 96.8 |
Adenosquamous carcinoma | 1 | 0.8 |
NOS | 3 | 2.4 |
EGFR mutation type | ||
Exon 19 deletion[a] | 87 | 69.6 |
Exon 21 L858R | 27 | 21.6 |
Others[b] | 11 | 8.8 |
Brain metastases at baseline | ||
No | 82 | 65.6 |
Yes | 42 | 33.6 |
Unknown | 1 | 0.8 |
Starting dose of afatinib once daily (OD) | ||
40 mg | 62 | 49.6 |
0 mg | 61 | 48.8 |
0 mg | 1 | 0.8 |
Unknown | 1 | 0.8 |